NCI Client: Alcresta Therapeutics introduces RELiZORB
Alcresta Therapeutics’ RELiZORB™ Increases Fat Absorption in Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition
RELiZORB significantly increased plasma levels of DHA and EPA fatty acids and patients report a decrease in the frequency and severity of gastrointestinal symptoms
RELiZORB is a first-of-its kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase. RELiZORB is designed for use…